FiercePharma

Novartis' first Kesimpta ad push offers break from relapsing MS 'drama'

Novartis’ first TV ad for Kesimpta offers the prospect of less drama—less relapsing multiple sclerosis drama, that is. During the commercial, phrases representing that drama such as “unpredictable ...
Seeking Alpha

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of ...
Seeking Alpha

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
WDAF-TV

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta ® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of ...
Nasdaq

Novartis : Six-Year Study Reveals Benefits Of Kesimpta In Newly Diagnosed Relapsing MS Patients

(RTTNews) - Novartis AG (NVS) said that an analysis of treatment-naive people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years ...
Nasdaq

Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS

Novartis AG NVS announced that the European Commission has approved its B-cell therapy Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (“RMS”) in adult patients with ...